v3.26.3
Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Statement of Cash Flows [Abstract]        
Net income (loss) $ 14,549,512 $ (111,334) $ 5,828,978 $ 236,586
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation 92,338 82,108 178,754 186,350
Common stock issued for services 35,200 35,200 54,750
Series B stock issued for services 14,100 14,100 792,200
Accounts receivable allowance 22,382 22,382 22,382
Fixed assets, net     (192,617) (207,973)
Acquired intangible assets 45,540 (9,357) (8,954) (11,615)
Change in assets and liabilities:        
Gross accounts receivable (11,742) (88,202) (163,415) 981,618
Prepaid 55,872 (364,395) (440,762) 246,856
Related party receivable (36,532,537) (5,172,027) (38,407,601) (1,682,450)
Accounts payable 191,628 291,278 (63,104) 49,337
Other current liabilities (1,301,578) (4,272,323) (3,195,117) 4,557,126
Accrued interest (2,787) 39,612 (28,097) 37,431
Client funds payable 1,885,820 5,219,961 (5,712,901) (18,693,481)
Fair value of trading position, net 1,267,725 (59,718) (576,716) 268,101
Operating lease (48,292) (88,531) (181,581) 672,245
Deferred taxes (186,506) 46,294 44,557 (513,163)
Related party guarantee     1,353,170
Tax receivable 275,609 (23,314) (22,439) 9,299
Trade receivables (88,986)    
Accrued income (2,017,206) 1,529,901 1,793,304 (1,037,574)
Right of use of assets (lease) 44,700 81,348 167,216 (938,571)
Accrued expenses, related party 620,497 7,500 12,787 (15,000)
Net cash provided by (used in) operating activities (21,138,011) (2,819,517) (40,918,408) (13,632,376)
Investing Activities:        
Capitalized software (464,777) (127,987) (316,937) (75,766)
Business acquisition seller’s note     2,000,000
Acquisition of Alchemy International Limited     8,933,118  
Changes in paid-in capital, common control     1,054,389 818,507
Purchases of fixed assets (8,142) (74,721)    
Investment in private entities 317    
Net cash provided by (used in) investing activities (472,602) (202,708) 11,670,570 742,741
Financing Activities:        
Borrowing from (payments to) line of credit 186,510 66,494 (3,985) 54,595
Net proceeds from CARES Act - paycheck protection program (4,771) (5,661) (14,991)
Net proceeds from SBA loan (4,252) (4,253) (8,506) (8,505)
Related party advances 32,831,092 (5,207,274) 21,204,630 7,199,501
Common stock issued for cash     20,000
Common stock issued for financing cost     8,900
Series A for cash and cancelation     (200)
Changes in NCI     16,503 (22,118)
Noncontrolling interest income     (31,389) 10,958
Changes in paid-in capital, common control 2,295,047 1,529,884    
Net cash provided by (used in) financing activities 35,308,397 (3,619,920) 21,171,592 7,248,140
Effect of exchange rates (217,936) 337,435 369,038 (298,009)
Change in noncontrolling interest share of subsidiary net assets (7,432) (8,989)    
Non-cash assignment of liquidity-provider balance included within cash and cash equivalents (5,257,670)    
Net increase (decrease) in cash 8,214,746 (6,313,699) (7,707,208) (5,939,504)
Cash, cash equivalents, and restricted cash at beginning of the period 17,669,749 25,376,957 25,376,957 31,316,461
Cash, cash equivalents, and restricted cash at end of the period 25,884,495 19,063,258 17,669,749 25,376,957
Cash paid for income taxes
Cash paid for interest
Non - cash investing and financing activities:        
Consideration paid directly by principal shareholder on behalf of the Company 250,000    
Less: carryover book value of net assets acquired (143,981)    
Deemed distribution to principal shareholder 106,019    
Common-control adjustment to additional paid-in capital 2,151,066 1,529,884    
Excess consideration allocated to acquired intangible assets on consolidation of ADS 1,280,522    
Supplemental non-cash disclosures:        
Cash and cash equivalents acquired in the common-control combination 99,198    
Noncontrolling interest movements recognized directly in equity $ (36,117) $ (8,989)